Prognostic indicators for poor risk epithelial ovarian carcinoma
- 15 August 1994
- Vol. 74 (4) , 1323-1328
- https://doi.org/10.1002/1097-0142(19940815)74:4<1323::aid-cncr2820740423>3.0.co;2-5
Abstract
Background. The objective of this study was to identify factors that categorize patients with epithelial ovarian carcinoma into favorable and unfavorable prognostic groups at the time of initial treatment. Methods. Data were analyzed from 51 women who were treated at Yale University, had an evaluable CA 125 half-life (t 0.5), and were followed for disease recurrence for at least 2 years. Results. Grade, maximum level of CA 125, and histology did not provide useful prognostic information. Stage, residual disease, minimum CA 125, and CA 125 t 0.5 individually were predictive of persistent disease or recurrence within 3 years of diagnosis with sensitivities of 97, 70, 34, and 49%, respectively, and specificities of 33, 83, 100, and 83%, respectively. When these factors are combined, defining an unfavorable prognostic group as those patients having residual disease greater than 1 cm, CA 125 t 0.5 greater than 12 days, or minimum CA 125 never falling below 35 U/ml, sensitivity and specificity were 96 and 65%, respectively, at 1 year of follow-up and 91 and 75%, respectively, at 3 years of follow-up. Conclusions. In those patients in whom residual small volume disease after primary surgery indicates a good prognosis, minimum CA 125 and CA 125 t 0.5 during chemotherapy can further categorize patients into favorable and unfavorable prognostic groups.Keywords
This publication has 12 references indexed in Scilit:
- An independent evaluation of the potential clinical usefulness of proposed CA-125 indices previously shown to be of prognostic significance in epithelial ovarian cancerBritish Journal of Cancer, 1992
- CA-125 in ovarian cancer: Relation between half-life, doubling time and survivalEuropean Journal of Cancer and Clinical Oncology, 1991
- CA 125 regression: A model for epithelial ovarian cancer responseAmerican Journal of Obstetrics and Gynecology, 1991
- The prognostic significance of CA 125 half-life in patients with ovarian cancer who have received primary chemotherapy after surgical cytoreductionAmerican Journal of Obstetrics and Gynecology, 1990
- Predictive value of CA 125 during early chemotherapy of advanced ovarian cancerGynecologic Oncology, 1990
- Use of CA-125 to predict survival of patients with ovarian carcinoma. North Thames Cooperative Group.Journal of Clinical Oncology, 1989
- Ovarian cancer: The prognostic value of the serum half-life of CA125 during induction chemotherapyGynecologic Oncology, 1988
- CA125 as a serum marker for poor prognosis in ovarian malignanciesGynecologic Oncology, 1987
- Ovarian cancer antigen CA125: a prospective clinical assessment of its role as a tumour markerBritish Journal of Cancer, 1984
- A Radioimmunoassay Using a Monoclonal Antibody to Monitor the Course of Epithelial Ovarian CancerNew England Journal of Medicine, 1983